Table 1 Patient characteristics.
Patient No | Sex | Age (years) | Diagnosis | Donor type | CMV serostatus | Time to CMV reactivation after HSCT | CMV infection/ disease | Peak CMV DNA titre (IU/mL) | Co-infections | aGVHD | cGVHD | T cell depletion strategy | GVHD prophylaxis | Chimerism | CMV antiviral treatment | Duration from CMV infection to CMV-CTLs therapy | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | M | 7 | TM | Haplo (father) | D + /R+ | 39 days | CMV pneumonia + retinitis | 1.84 × 104 (plasma) | HBV | - | Liver | ATG | PTCY + FK506 + MMF + LDMTX | 40–99% for the first 4 months then >99% after 5 months. | GCV + FOS + CMV-IVIG | 6 months | -Resolution of CMV DNAemia in 4 weeks. -Complete resolution of pneumonia in 2 weeks. -Blindness caused by CMV retinitis. |
2 | F | 7 | TM | Haplo (father) | D + /R− | 63 days | CMV pneumonia | 6.78 × 102 (plasma) | PVB19, EBV DNAemia | - | Skin and liver | ATG | PTCY + FK506 + MMF + LDMTX | >95% | GCV + FOS | 29 days | -Resolution of CMV DNAemia in 4 weeks. -Complete resolution of pneumonia in 2 weeks. |
3 | M | 7 | TM | Haplo (sister) | D + /R− | 79 days | CMV pneumonia | 1.44 × 103 (BAL fluid), negative plasma CMV DNA | - | - | - | ATG | PTCY + FK506 + MMF + LDMTX | >99% | GCV + FOS + CMV-IVIG | 13 days | -Resolution of CMV DNAemia in 3 weeks. -Complete resolution of pneumonia in 12 weeks. |
4 | F | 3 | TM | MSD (brother) | D + /R+ | 28 days | CMV pneumonia | 2.26 × 104 (BAL fluid), 4.16 × 103 (plasma) | RSV | - | - | ATG | CSA + MMF + LDMTX | >99% | GCV | 12 days | -Resolution of CMV DNAemia in 3 weeks. -Complete resolution of pneumonia in 4 weeks. |
5 | M | 4 | TM | Haplo (father) | D + /R− | 48 days | CMV pneumonia | 7.53 × 102 (plasma), 7.70 × 102 (BAL fluid) | EBV DNAemia, bacterial enteritis | - | - | ATG | PTCY + FK506 + MMF + LDMTX | >99% | GCV + FOS + CMV-IVIG | 19 days | -Resolution of CMV DNAemia in 3 weeks. -Complete resolution of pneumonia in 12 weeks. |
6 | M | 1 | SAA | Haplo (father) | D + /R+ | 29 days | CMV pneumonia | 8.48 × 102 (plasma), CMV DNA in BAL fluid confirmed by NGS | Fungal meningitis, bacterial enteritis | III | - | ATG | PTCY + FK506 + MMF + LDMTX | >99% | GCV + CMV-IVIG | 15 days | -Resolution of CMV DNAemia in 4 weeks. -Complete resolution of pneumonia in 6 weeks. |
7 | F | 5 | TM | Haplo (mother) | D + /R+ | 45 days | CMV pneumonia | 4.55 × 102 (plasma), 9.35 × 103 (BAL fluid) | EBV DNAemia, fungal pneumonia | II | - | ATG | PTCY + FK506 + MMF + LDMTX | 60–80% for the first month then >99% after 2 months. | GCV + CMV-IVIG | 20 days | -Resolution of CMV DNAemia in 3 weeks. -Complete resolution of pneumonia in 6 weeks. |
8 | F | 5 | TM | Haplo (father) | D + /R+ | 40 days | CMV pneumonia | 7.14 × 102 (plasma), 2.48 × 102 (BAL fluid) | - | IV | - | ATG | PTCY + FK506 + MMF + LDMTX | >99% | GCV + CMV-IVIG | 21 days | -Resolution of CMV DNAemia in 3 weeks. -Complete resolution of pneumonia in 5 weeks. |
9 | F | 4 | TM | Haplo (sister) | D + /R+ | 33 days | Refractory CMV DNAemia | 5.78 × 103 (plasma) | EBV DNAemia | II | - | ATG | PTCY + CSA + MMF + LDMTX | <50% for the first months then >99% after 2 months. | GCV + CMV-IVIG | 19 days | Resolution of CMV DNAemia in 2 weeks. |
10 | M | 2 | SAA | Haplo (father) | D + /R+ | 27 days | CMV pneumonia | 1.33 × 103 (plasma), 1.35 × 103 (BAL fluid) | Invasive fungal infection, adenoviral enteritis | - | - | ATG | PTCY + CSA + MMF + LDMTX | >99% | GCV + FOS + CMV-IVIG | 23 days | -Resolution of CMV DNAemia in 4 weeks. -Complete resolution of pneumonia in 5 weeks. |
